Michel Boutin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/616944/publications.pdf

Version: 2024-02-01

46 papers	1,067 citations	430874 18 h-index	414414 32 g-index
46 all docs	46 docs citations	46 times ranked	1112 citing authors

#	Article	IF	Citations
1	Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics. Analytical Chemistry, 2012, 84, 2745-2753.	6.5	82
2	Multiplex Analysis of Novel Urinary Lyso-Gb₃-Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry. Analytical Chemistry, 2013, 85, 1743-1752.	6.5	72
3	Multiplex Tandem Mass Spectrometry Analysis of Novel Plasma Lyso-Gb₃-Related Analogues in Fabry Disease. Analytical Chemistry, 2014, 86, 3476-3483.	6.5	71
4	Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. Analytical Chemistry, 2016, 88, 1856-1863.	6.5	68
5	Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clinica Chimica Acta, 2015, 438, 195-204.	1.1	62
6	Lentivirus-mediated gene therapy for Fabry disease. Nature Communications, 2021, 12, 1178.	12.8	58
7	A Metabolomic Study To Identify New Globotriaosylceramide-Related Biomarkers in the Plasma of Fabry Disease Patients. Analytical Chemistry, 2013, 85, 9039-9048.	6.5	56
8	LCâ€“MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Clinica Chimica Acta, 2012, 414, 273-280.	1.1	53
9	Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clinica Chimica Acta, 2017, 466, 185-193.	1.1	44
10	Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. Journal of Medical Genetics, 2019, 56, 548-556.	3.2	43
11	Metabolomic Discovery of Novel Urinary Galabiosylceramideâ€‰Analogs as Fabry Disease Biomarkers. Journal of the American Society for Mass Spectrometry, 2015, 26, 499-510.	2.8	42
12	Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. Orphanet Journal of Rare Diseases, 2016, 11, 8.	2.7	42
13	The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiology of Disease, 2018, 110, 68-81.	4.4	38
14	Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. Molecular Therapy - Methods and Clinical Development, 2017, 5, 241-258.	4.1	36
15	Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. Analytical Chemistry, 2017, 89, 13382-13390.	6.5	31
16	Globotriaosylsphingosine (Lysoâ€Gb₃) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 2018, 41, 239-247.	3.6	25
17	Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. Clinica Chimica Acta, 2016, 452, 191-198.	1.1	23
18	Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clinica Chimica Acta, 2015, 447, 96-104.	1.1	22

#	Article	IF	Citations
19	Evaluation of urinary keratan sulfate disaccharides in MPS IVA patients using UPLCâ€“MS/MS. Bioanalysis, 2016, 8, 179-191.	1.5	17
20	Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clinica Chimica Acta, 2019, 495, 67-75.	1.1	17
21	Tandem Mass Spectrometry Quantitation of Lysoâ€Gb 3 and Six Related Analogs in Plasma for Fabry Disease Patients. Current Protocols in Human Genetics, 2016, 90, 17.23.1-17.23.9.	3.5	14
22	Relative distribution of Gb‹sub›3‹/sub› isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis, 2016, 8, 1793-1807.	1.5	14
23	The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease. Clinica Chimica Acta, 2020, 500, 120-127.	1.1	13
24	Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. Journal of Medical Genetics, 2021, 58, 692-700.	3.2	13
25	Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. International Journal of Molecular Sciences, 2020, 21, 7869.	4.1	11
26	Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease. Gastroenterology, 2020, 159, 1602-1604.	1.3	11
27	Highâ€Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb 3) in Urine Collected on Filter Paper. Current Protocols in Human Genetics, 2017, 93, 17.26.1-17.26.12.	3.5	10
28	Analysis of globotriaosylceramide (Gb 3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. Analytica Chimica Acta, 2018, 1015, 35-49.	5.4	9
29	Fabry Disease Biomarkers: Analysis of Urinary Lysoâ€Gb 3 and Seven Related Analogs Using Tandem Mass Spectrometry. Current Protocols in Human Genetics, 2016, 90, 17.22.1-17.22.12.	3.5	8
30	Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. Diagnostics, 2019, 9, 195.	2.6	8
31	Mass spectrometry analysis of urinary methylmalonic acid to screen for metabolic vitamin B deficiency in older adults. Bioanalysis, 2020, 12, 693-705.	1.5	8
32	Vitamin B-12 Intake from Dairy but Not Meat Is Associated with Decreased Risk of Low Vitamin B-12 Status and Deficiency in Older Adults from Quebec, Canada. Journal of Nutrition, 2022, 152, 2483-2492.	2.9	8
33	Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model. Journal of Lipid Research, 2020, 61, 1410-1423.	4.2	7
34	Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. Future Science OA, 2016, 2, FSO147.	1.9	6
35	Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLCâ€“MS/MS. Bioanalysis, 2019, 11, 727-740.	1.5	6
36	Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry. International Journal of Neonatal Screening, 2021, 7, 18.	3.2	4

#	Article	IF	Citations
37	Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles. International Journal of Molecular Sciences, 2020, 21, 6114.	4.1	3
38	Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry. Diagnostics, 2022, 12, 1414.	2.6	3
39	Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis, 2016, 8, 1441-1450.	1.5	2
40	Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. Molecular Genetics and Metabolism Reports, 2020, 24, 100618.	1.1	2
41	Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1. Journal of Proteome Research, 2022, 21, 1321-1329.	3.7	2
42	Highâ€Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Nonâ€Methylated Gb 3 Isoforms Using Tandem Mass Spectrometry. Current Protocols in Human Genetics, 2016, 91, 17.24.1-17.24.11.	3.5	1
43	Lysosphingolipid urine screening test using mass spectrometry for theÂearly detection of lysosomal storage disorders. Bioanalysis, 2022, 14, 289-306.	1.5	1
44	Methylmalonic acid analysis using urine filter paper samples to screen for metabolic vitamin B₁₂ deficiency in older adults. Bioanalysis, 2022, 14, 615-626.	1.5	1
45	Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. Diagnostics, 2020, 10, 69.	2.6	0
46	Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. Bioanalysis, 2022, 14, 223-240.	1.5	0